SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic Stroke

MOUNTAIN VIEW, Calif., Jan. 14, 2013 /PRNewswire/ -- SanBio Inc. today announced the successful enrollment of the second dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 12 patients, of a planned total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University, the University of Pittsburgh and Northwestern University. No safety concerns have been attributed to the cell therapy product. For details regarding this clinical trial, please refer to www.strokeclinicaltrial.org.

SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke.  "The successful completion of the first two dose cohorts of this pioneering clinical trial is a clear indication of the dedication and professionalism of the entire team," said Keita Mori, SanBio CEO.

SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke.  Product safety is the primary focus of the study but various measurements of efficacy are also being tested.

"We are pleased with the safety findings of the study thus far," said Dr. Ernest Yankee, SanBio's Executive Vice President of Development. "We anticipate completing the enrollment of the third and final dose cohort early in the year and reporting the results shortly thereafter."

About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors.  SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: www.san-bio.com

SOURCE SanBio